Nongenomic Mechanism-Mediated Renal Fibrosis-Decreasing Activity of a Series of PPAR-γ Agonists
The number of dialysis patients with chronic kidney disease (CKD) is gradually increasing, especially in Westernized countries. Renal fibrosis is a basic risk factor for CKD, and CKD in turn is considered to be an independent risk factor for cardiovascular disease. CKD is defined as a progressive loss of function over a long period of time. It affects patients worldwide and is associated with a high morbidity and mortality rate. CKD affects more than 13% of the population in the United States (USA)  and in Europe .
KeywordsChronic Kidney Disease Renal Fibrosis Alkoxyl Group Estrogen Receptor Agonist Phenylpropanoic Acid